Finny Monickaraj1,2, Sreenivasa R Oruganti3, Paul McGuire4, Arup Das5,6,7. 1. Department of Surgery, University of New Mexico School of Medicine, MSC10 5610, Albuquerque, NM, 87131, USA. 2. New Mexico VA Health Care System, Albuquerque, NM, USA. 3. Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA. 4. Department of Cell Biology & Physiology, University of New Mexico School of Medicine, Albuquerque, NM, USA. 5. Department of Surgery, University of New Mexico School of Medicine, MSC10 5610, Albuquerque, NM, 87131, USA. adas@unm.edu. 6. New Mexico VA Health Care System, Albuquerque, NM, USA. adas@unm.edu. 7. Department of Cell Biology & Physiology, University of New Mexico School of Medicine, Albuquerque, NM, USA. adas@unm.edu.
Abstract
PURPOSE: We have previously shown that the chemokine CCL2 plays an important role in monocyte trafficking into the retina and alteration of the BRB in an animal model of diabetic retinopathy. In this study, we examined the effect of pharmacologically targeting the chemokine pathway to reduce the increased retinal vascular permeability in this model. METHODS: C57BL/6 J mice were made diabetic using streptozotocin. After 4 months of diabetes, mice (n = 10) were treated by intraperitoneal injections of TAK-779 (dual CCR2/CCR5 inhibitor) (30 mg/kg) daily for 2 weeks. Retinal vascular permeability and protein expression were done using western blot. The SDF-1 levels were measured by ELISA. Immune cell infiltration in the retinas was measured using flow cytometry. RESULTS: The dual inhibitor significantly decreased retinal vascular permeability in diabetic animals. There was a significant reduction in macrophage/microglia infiltration in the retinas of treated animals. Levels of SDF-1 and ICAM-1 were significantly reduced and the tight junction protein ZO-1 level was increased, and phospho-VE-Cad was significantly reduced with drug treatment. CONCLUSIONS: A chemokine receptor inhibitor (CCR2/CCR5) can reduce retinal vascular permeability in diabetic animals. Targeting the chemokine pathway pharmacologically may be used as a novel therapeutic strategy in management of diabetic macular edema.
PURPOSE: We have previously shown that the chemokine CCL2 plays an important role in monocyte trafficking into the retina and alteration of the BRB in an animal model of diabetic retinopathy. In this study, we examined the effect of pharmacologically targeting the chemokine pathway to reduce the increased retinal vascular permeability in this model. METHODS: C57BL/6 J mice were made diabetic using streptozotocin. After 4 months of diabetes, mice (n = 10) were treated by intraperitoneal injections of TAK-779 (dual CCR2/CCR5 inhibitor) (30 mg/kg) daily for 2 weeks. Retinal vascular permeability and protein expression were done using western blot. The SDF-1 levels were measured by ELISA. Immune cell infiltration in the retinas was measured using flow cytometry. RESULTS: The dual inhibitor significantly decreased retinal vascular permeability in diabetic animals. There was a significant reduction in macrophage/microglia infiltration in the retinas of treated animals. Levels of SDF-1 and ICAM-1 were significantly reduced and the tight junction protein ZO-1 level was increased, and phospho-VE-Cad was significantly reduced with drug treatment. CONCLUSIONS: A chemokine receptor inhibitor (CCR2/CCR5) can reduce retinal vascular permeability in diabetic animals. Targeting the chemokine pathway pharmacologically may be used as a novel therapeutic strategy in management of diabetic macular edema.
Authors: Jason M Butler; Steven M Guthrie; Mehmet Koc; Aqeela Afzal; Sergio Caballero; H Logan Brooks; Robert N Mames; Mark S Segal; Maria B Grant; Edward W Scott Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: Sahng Y Kim; Mary A Johnson; D Scott McLeod; Theresa Alexander; Barbara C Hansen; Gerard A Lutty Journal: Diabetes Date: 2005-05 Impact factor: 9.461
Authors: J K Harrison; Y Jiang; S Chen; Y Xia; D Maciejewski; R K McNamara; W J Streit; M N Salafranca; S Adhikari; D A Thompson; P Botti; K B Bacon; L Feng Journal: Proc Natl Acad Sci U S A Date: 1998-09-01 Impact factor: 11.205
Authors: Matthew D Silverman; David O Zamora; Yuzhen Pan; Paul V Texeira; Seung-Hee Baek; Stephen R Planck; James T Rosenbaum Journal: Invest Ophthalmol Vis Sci Date: 2003-04 Impact factor: 4.799
Authors: Meredith J Giblin; Taylor E Smith; Garrett Winkler; Hannah A Pendergrass; Minjae J Kim; Megan E Capozzi; Rong Yang; Gary W McCollum; John S Penn Journal: Biochim Biophys Acta Mol Basis Dis Date: 2021-07-31 Impact factor: 5.187